MedKoo Cat#: 407497 | Name: PCI-33380
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PCI-33380 is a potent and irreversible Bruton's Tyrosine Kinase (BTK) inhibitor with a fluorescent probe. PCI-33380 was designed based on the ibrutinib scaffold and has been used in both cellular and in vivo studies that demonstrated the connection between the inhibitor binding event and phenotypic readouts of cellular responses due to the inhibition of Btk functions. Furthermore, the use of fluorescent probes in clinical trials has played an important role in determining the appropriate dosage of drugs for patients.

Chemical Structure

PCI-33380
PCI-33380
CAS#1022899-36-0

Theoretical Analysis

MedKoo Cat#: 407497

Name: PCI-33380

CAS#: 1022899-36-0

Chemical Formula: C46H52BF2N11O3

Exact Mass: 855.4316

Molecular Weight: 855.80

Elemental Analysis: C, 64.56; H, 6.12; B, 1.26; F, 4.44; N, 18.00; O, 5.61

Price and Availability

Size Price Availability Quantity
2mg USD 150.00 Ready to ship
5mg USD 330.00 Ready to ship
10mg USD 550.00 Ready to ship
25mg USD 1,050.00 Ready to ship
50mg USD 1,750.00 Ready to ship
100mg USD 3,150.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
PCI-33380; PCI 33380; PCI33380;
IUPAC/Chemical Name
(E)-N-(2-(4-(4-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-4-oxobut-2-en-1-yl)piperazin-1-yl)ethyl)-3-(5,5-difluoro-7,9-dimethyl-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)propanamide
InChi Key
YUGFMNZIROEBNV-YRNVUSSQSA-N
InChi Code
InChI=1S/C46H52BF2N11O3/c1-32-28-33(2)58-40(32)29-36-15-14-35(59(36)47(58,48)49)16-19-41(61)51-20-23-56-26-24-55(25-27-56)21-7-11-42(62)57-22-6-8-37(30-57)60-46-43(45(50)52-31-53-46)44(54-60)34-12-17-39(18-13-34)63-38-9-4-3-5-10-38/h3-5,7,9-15,17-18,28-29,31,37H,6,8,16,19-27,30H2,1-2H3,(H,51,61)(H2,50,52,53)/b11-7+
SMILES Code
O=C(NCCN1CCN(C/C=C/C(N2CC(N3N=C(C4=CC=C(OC5=CC=CC=C5)C=C4)C6=C(N)N=CN=C63)CCC2)=O)CC1)CCC7=CC=C8N7B(F)(F)[N]9=C(C)C=C(C)C9=C8
Appearance
Dark-red to brown-red solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Solvent mg/mL mM
Solubility
DMSO 45.0 52.60
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 855.80 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Honigberg, L. A., Smith, A. M., Chen, J., Thiemann, P., & Verner, E. (2007). Targeting Btk in Lymphoma: PCI-32765 Inhibits Tumor Growth in Mouse Lymphoma Models and a Fluorescent Analog of PCI-32765 Is an Active-Site Probe That Enables Assessment of Btk Inhibition In Vivo. Sivina, M., Kreitman, R. J., Arons, E., Ravandi, F., & Burger, J. A. (2014). The bruton tyrosine kinase inhibitor ibrutinib (PCI‐32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. British journal of haematology, 166(2), 177-188. Zuo, Y., Shi, Y., Li, X., Teng, Y., & Pan, Z. (2015). A novel 2, 5-diaminopyrimidine-based affinity probe for Bruton’s tyrosine kinase. Scientific Reports, 5(1), 16136.